Cowen reissued their buy rating on shares of Acceleron Pharma (NASDAQ:XLRN) in a research report sent to investors on Sunday, AnalystRatings.com reports.

Several other analysts also recently weighed in on the company. Citigroup cut their target price on Acceleron Pharma from $61.00 to $52.00 and set a buy rating on the stock in a research note on Tuesday, September 17th. Credit Suisse Group set a $58.00 target price on Acceleron Pharma and gave the company a buy rating in a research note on Monday, August 26th. Morgan Stanley cut their target price on Acceleron Pharma from $52.00 to $48.00 and set an equal weight rating on the stock in a research note on Friday. ValuEngine raised Acceleron Pharma from a buy rating to a strong-buy rating in a research note on Thursday, August 8th. Finally, JPMorgan Chase & Co. cut their target price on Acceleron Pharma from $61.00 to $58.00 and set an overweight rating on the stock in a research note on Tuesday, August 6th. Six research analysts have rated the stock with a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the stock. The stock has a consensus rating of Buy and an average target price of $57.83.

Acceleron Pharma stock traded up $0.79 during mid-day trading on Friday, hitting $40.26. 333,356 shares of the company’s stock traded hands, compared to its average volume of 361,323. The firm has a 50 day moving average price of $42.51 and a 200 day moving average price of $42.27. The company has a quick ratio of 17.11, a current ratio of 17.11 and a debt-to-equity ratio of 0.05. The company has a market cap of $2.12 billion, a PE ratio of -15.54 and a beta of 1.25. Acceleron Pharma has a one year low of $37.01 and a one year high of $59.08.

Acceleron Pharma (NASDAQ:XLRN) last announced its earnings results on Monday, August 5th. The biopharmaceutical company reported ($0.34) earnings per share for the quarter, missing the consensus estimate of ($0.24) by ($0.10). The business had revenue of $27.67 million for the quarter, compared to the consensus estimate of $28.72 million. Acceleron Pharma had a negative net margin of 318.84% and a negative return on equity of 29.51%. The firm’s revenue was up 649.9% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.63) EPS. On average, analysts expect that Acceleron Pharma will post -2.33 earnings per share for the current fiscal year.

In other news, CFO Kevin F. Mclaughlin sold 8,000 shares of the business’s stock in a transaction on Tuesday, September 10th. The stock was sold at an average price of $45.30, for a total value of $362,400.00. Following the sale, the chief financial officer now owns 22,452 shares of the company’s stock, valued at approximately $1,017,075.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Habib J. Dable sold 5,625 shares of the business’s stock in a transaction on Tuesday, September 10th. The stock was sold at an average price of $45.23, for a total value of $254,418.75. Following the completion of the sale, the chief executive officer now directly owns 71,227 shares in the company, valued at approximately $3,221,597.21. The disclosure for this sale can be found here. Insiders sold a total of 25,228 shares of company stock worth $1,138,448 in the last three months. Company insiders own 2.50% of the company’s stock.

Several institutional investors and hedge funds have recently bought and sold shares of the company. Marshall Wace LLP boosted its stake in Acceleron Pharma by 20,146.2% during the 1st quarter. Marshall Wace LLP now owns 208,333 shares of the biopharmaceutical company’s stock worth $9,702,000 after purchasing an additional 207,304 shares during the last quarter. Marshall Wace North America L.P. boosted its stake in Acceleron Pharma by 6,720.3% during the 1st quarter. Marshall Wace North America L.P. now owns 383,166 shares of the biopharmaceutical company’s stock worth $17,844,000 after purchasing an additional 377,548 shares during the last quarter. MetLife Investment Advisors LLC boosted its stake in Acceleron Pharma by 10.9% during the 1st quarter. MetLife Investment Advisors LLC now owns 19,308 shares of the biopharmaceutical company’s stock worth $899,000 after purchasing an additional 1,902 shares during the last quarter. Metropolitan Life Insurance Co NY boosted its stake in Acceleron Pharma by 12.6% during the 1st quarter. Metropolitan Life Insurance Co NY now owns 13,963 shares of the biopharmaceutical company’s stock worth $650,000 after purchasing an additional 1,563 shares during the last quarter. Finally, FMR LLC boosted its stake in Acceleron Pharma by 6.3% during the 1st quarter. FMR LLC now owns 7,363,953 shares of the biopharmaceutical company’s stock worth $342,939,000 after purchasing an additional 435,414 shares during the last quarter. 90.10% of the stock is currently owned by institutional investors.

About Acceleron Pharma

Acceleron Pharma Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. Its therapeutic candidates include luspatercept, which is in Phase III clinical trials for the treatment of myelodysplastic syndromes and beta-thalassemia; Phase II clinical trials for the treatment of patients with transfusion-dependent beta-thalassemia and myelofibrosis.

Read More: The Discount Rate – What You Need to Know

Analyst Recommendations for Acceleron Pharma (NASDAQ:XLRN)

Receive News & Ratings for Acceleron Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acceleron Pharma and related companies with MarketBeat.com's FREE daily email newsletter.